Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.6640
+0.0308 (4.86%)
At close: Sep 26, 2025, 4:00 PM EDT
0.6645
+0.0005 (0.08%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Sangamo Therapeutics Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Sangamo Therapeutics stock ranges from a low of $2.00 to a high of $10. The average analyst price target of $5.29 forecasts a 696.69% increase in the stock price over the next year.
Price Target: $5.29 (+696.69%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Sangamo Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,406.02% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,406.02% | Jun 24, 2025 |
| Barclays | Barclays | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +653.01% | May 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +1,406.02% | Apr 7, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $2 | Hold | Reiterates | $2 | +201.20% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
74.26M
from 57.80M
Increased by 28.47%
Revenue Next Year
61.08M
from 74.26M
Decreased by -17.74%
EPS This Year
-0.30
from -0.49
EPS Next Year
-0.29
from -0.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 130.9M | 123.9M | |||
| Avg | 74.3M | 61.1M | |||
| Low | 34.0M | 8.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 126.5% | 66.9% | |||
| Avg | 28.5% | -17.7% | |||
| Low | -41.2% | -88.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.13 | -0.13 | |||
| Avg | -0.30 | -0.29 | |||
| Low | -0.42 | -0.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.